Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses-Reference-Cited by-同舟云学术

Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses

Published:2020-08-28 Issue:1 Volume:24 Page:244-252
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Lee Hsiang Ying^ORCID,Chen Hsiao-Ling,Teoh Jeremy Yuen-Chun^ORCID,Chen Tun-Chieh,Hao Shao-Yuan,Tsai Hsin-Yi,Huang Wei-Hsuan,Juan Yung-Shun,Cheng Hao-Min,Chang Hsiu-Mei^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

https://www.nature.com/articles/s41391-020-00275-3.pdf

Reference49 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

2. Huggins C, Clark PJ. Quantitative studies of prostatic secretion: Ii. The effect of castration and of estrogen injection on the normal and on the hyperplastic prostate glands of dogs. J Exp Med. 1940;72:747–62.

3. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65:1180–92.

4. Akaza H, Usami M, Hinotsu S, Ogawa O, Kagawa S, Kitamura T, et al. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol. 2004;34:329–36.

5. Cooperberg MR, Hinotsu S, Namiki M, Carroll PR, Akaza H. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer. BJU Int. 2016;117:102–9.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer;JAMA Network Open;2024-08-16

2. Assessment of Cardiovascular Events Caused by New-Generation Androgen Receptor Pathway Inhibitors Used for Prostate Cancer: A Real-World Study in Japan;Oncology;2024-08-14

3. Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer;JAMA Oncology;2024-07-01

4. Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials;Clinical Genitourinary Cancer;2024-06

5. Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy;European Urology Oncology;2024-06